Active Ingredient History
Foralumab (TZLS-401), being researched by Tiziana Life Sciences) is a fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex. It is currently being studied in a randomized, double-blind placebo-controlled, multicenter dose-ranging study in a nasal formulation in patients with non-active secondary progressive multiple sclerosis (SPMS). Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
COVID-19 (Phase 2)
Crohn Disease (Phase 1)
Diabetes Mellitus, Type 2 (Phase 2)
Multiple Sclerosis (Phase 1)
Multiple Sclerosis, Chronic Progressive (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue